Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

646 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A randomized, open-label, clinical trial examined the effects of canagliflozin on albuminuria and eGFR decline using an individual pre-intervention eGFR slope.
Miyamoto S, Heerspink HJL, de Zeeuw D, Sakamoto K, Yoshida M, Toyoda M, Suzuki D, Hatanaka T, Nakamura T, Kamei S, Murao S, Hida K, Ando S, Akai H, Takahashi Y, Kitada M, Sugano H, Nunoue T, Nakamura A, Sasaki M, Nakatou T, Fujimoto K, Kawanami D, Wada T, Miyatake N, Kuramoto H, Shikata K; CANPIONE study Investigators. Miyamoto S, et al. Among authors: kitada m. Kidney Int. 2024 Nov;106(5):972-984. doi: 10.1016/j.kint.2024.08.019. Epub 2024 Aug 30. Kidney Int. 2024. PMID: 39216659 Free article. Clinical Trial.
[Study of Combined Small Cell Lung Cancer].
Yoshino R, Nakatsubo M, Ujiie N, Ito A, Yoshida N, Kitada M. Yoshino R, et al. Among authors: kitada m. Kyobu Geka. 2024 Aug;77(8):563-566. Kyobu Geka. 2024. PMID: 39205407 Japanese.
Eribulin versus S-1 as first or second-line chemotherapy to assess health-related quality of life and overall survival in HER2-negative metastatic breast cancer (RESQ study): a non-inferiority, randomised, controlled, open-label, phase 3 trial.
Takahashi M, Kikawa Y, Kashiwabara K, Taira N, Iwatani T, Shimozuma K, Ohtani S, Yoshinami T, Watanabe J, Kashiwaba M, Watanabe KI, Kitada M, Sakaguchi K, Tanabe Y, Aihara T, Mukai H. Takahashi M, et al. Among authors: kitada m. EClinicalMedicine. 2024 Jul 16;74:102715. doi: 10.1016/j.eclinm.2024.102715. eCollection 2024 Aug. EClinicalMedicine. 2024. PMID: 39109189 Free PMC article.
Characteristics of Invasive Cribriform Carcinoma.
Yoshino R, Nakatsubo M, Ujiie N, Ito A, Yoshida N, Kitada M. Yoshino R, et al. Among authors: kitada m. Cancer Invest. 2024 Sep;42(8):690-696. doi: 10.1080/07357907.2024.2383930. Epub 2024 Jul 26. Cancer Invest. 2024. PMID: 39058247
TP53 signature predicts pathological complete response after neoadjuvant chemotherapy for breast cancer: Observational and confirmational study using prospective study cohorts.
Takahashi S, Sato N, Kaneko K, Masuda N, Kawai M, Hirakawa H, Nomizu T, Iwata H, Ueda A, Ishikawa T, Bando H, Inoue Y, Ueno T, Ohno S, Kubo M, Yamauchi H, Okamoto M, Tokunaga E, Kamigaki S, Aogi K, Komatsu H, Kitada M, Uemoto Y, Toyama T, Yamamoto Y, Yamashita T, Yanagawa T, Yamashita H, Matsumoto Y, Toi M, Miyashita M, Ishida T, Fujishima F, Sato S, Yamaguchi T, Takahashi F, Ishioka C. Takahashi S, et al. Among authors: kitada m. Transl Oncol. 2024 Oct;48:102060. doi: 10.1016/j.tranon.2024.102060. Epub 2024 Jul 24. Transl Oncol. 2024. PMID: 39047382 Free PMC article.
Prognostic value of the 21-Gene Breast Recurrence Score® assay for hormone receptor-positive/human epidermal growth factor 2-negative advanced breast cancer: subanalysis from Japan Breast Cancer Research Group-M07 (FUTURE trial).
Iwamoto T, Niikura N, Watanabe K, Takeshita T, Kikawa Y, Kobayashi K, Iwakuma N, Okamura T, Kobayashi T, Katagiri Y, Kitada M, Tomioka N, Miyoshi Y, Shigematsu H, Miyashita M, Ishiguro H, Masuda N, Saji S. Iwamoto T, et al. Among authors: kitada m. Breast Cancer Res Treat. 2024 Nov;208(2):253-262. doi: 10.1007/s10549-024-07414-7. Epub 2024 Jun 26. Breast Cancer Res Treat. 2024. PMID: 38922548
646 results